<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904875</url>
  </required_header>
  <id_info>
    <org_study_id>PI2019_843_0008</org_study_id>
    <nct_id>NCT03904875</nct_id>
  </id_info>
  <brief_title>Air Pollution and COPD Exacerbation</brief_title>
  <acronym>BePoPi</acronym>
  <official_title>Impact of Air Pollution on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Haut de France. BePoPi Project.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinique de l'Europe, Amiens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an excess of hospitalization rates for acute exacerbation of COPD in Picardy
      compared to the national data. A first study realized in Picardy has shown a link between air
      quality and COPD. Nevertheless, the particles type is unknown and according to it, impact on
      COPD could be different. The investigator goal is to find a correlation between acute
      exacerbation of COPD consultation rate and daily ultra thin particles in Haut de France. The
      investigators will correlate the particles composition with daily acute exacerbation of COPD
      rate. All COPD patients with a diagnosis of acute exacerbation in emergency room in
      University Hospital of Amiens-Picardie and Lille, and Clinique de l'Europe between 01/01/2020
      and 31/12/2020 will be included. For each patient, home and work address will be collected.
      The duration of 1 year was chosen to take into account seasonal variations. In parallel, a
      daily report of the rate of ozone, particles (PM2.5 and PM10), dioxide nitrogen but also
      odours and pollens will be done by ATMO Haut de France.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>daily rate of COPD exacerbation consultation in the emergency room of the 3 centers</measure>
    <time_frame>every day during 12 months</time_frame>
    <description>daily rate of COPD exacerbation consultation in the emergency room of the 3 centers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ultrathin particles quantity in the air</measure>
    <time_frame>every day during 12 months</time_frame>
    <description>ultrathin particles quantity will be determined by the air of &quot;Haut de France&quot; by the company ATMO Haut de France.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chemical composition ultrathin particles</measure>
    <time_frame>every day during 12 months</time_frame>
    <description>chemical composition ultrathin particles will be determined by the air of &quot;Haut de France&quot; by the company ATMO Haut de France.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Pollution; Exposure</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collection of data about each acute exacerbation of COPD</intervention_name>
    <description>COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All COPD patients with a diagnosis of acute exacerbation in emergency room in University
        Hospital of Amiens-Picardie and Lille, and Clinique de l'Europe between 01/01/2020 and
        31/12/2020 will be included. Home and work address and spirometric data will be collected.
        Atmo Hauts-de-France will collect daily data on PM10, PM2,5, NO2 et O3 in Amiens and Lille
        metropoles. Odours and pollens will be collected too by ATMO Haut de France.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patients with a diagnosis of acute exacerbation of COPD in the emergency room of
             Amiens and Lille centers

          -  Adults

          -  Patients able to express consent

          -  signed written informed consent form

          -  covered by national health insurance

        Exclusion Criteria:

          -  patients non covered by national health insurance

          -  patients not able to express consent

          -  minors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damien Basille, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Andrejak, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Jounieaux, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Benoit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique de l'Europe, Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youcef Douadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique de l'Europe, Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Le Rouzic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damien Basille, MD</last_name>
    <phone>(33)322450175</phone>
    <email>basille.damien@chu-amiens.fr</email>
  </overall_contact>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pollution</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>ultrathin particles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

